NOVEL ANTAGONISTS OF THE TOLL-LIKE RECEPTOR 4

• US 20100168058A1
• Filed: 10/02/2006
• Published: 07/01/2010
• Est. Priority Date: 10/02/2006
• Status: Abandoned Application

• Current Assignee: Stichting Katholieke Universiteit
• Original Assignee: Stichting Katholieke Universiteit
• Inventors: JOOSTEN, Leonardus Antonius B.
• Application Number:
  US12/443,681
• Publication Number:
  US 20100168058A1
• Time in Patent Office: Days
• US Class Current: 514/54
• CPC Class Codes: A61K 31/739 Lipopolysaccharides
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis

Abstract

The present invention relates to a novel antagonist of the Toll-like receptor 4 (TLR-4). More specifically, the present invention relates to a lipopolysaccharide (LPS) isolated from the bacterium Bartonella quintana as a novel antagonist of the Toll-like receptor 4 (TLR-4). Further, the present invention relates to the use of said natural antagonist for the treatment of an autoimmune or inflammatory disease in a mammal and specifically for the treatment of rheumatoid arthritis (RA). Furthermore, the present invention relates to pharmaceutical compositions comprising a lipopolysaccharide (LPS) isolated from the bacterium Bartonella quintana.

Claims

1. Use of Bartonella quintana lipopolysaccharide or a functional equivalent fragment thereof for the preparation of a medicament for the treatment of an autoimmune disease, an autoinflammatory disease, or an infectious disease in a mammal.

2. Use according to claim 1, wherein the mammal is a human mammal.

3. Use according to claim 2, wherein the treatment comprises inhibition of the toll-like receptor signaling.

4. Use according to claim 1, wherein the treatment comprises inhibition of the toll-like receptor 4 (TLR-4)

5. Use according to claim 1, wherein the autoimmune or inflammatory disease is selected from the group consisting of rheumatoid arthritis, Crohn'"'"'s disease, bacterial, viral and fungal infections, bacterial, viral and fungal infections resulting in secondary side-effects, SIRS, sepsis, atherosclerosis, type I diabetes mellitus, Wegener'"'"'s granulomatosis, ulcerative colitis, systemic lupus erythemotosis (SLE), psoriasis, and multiple sclerosis.

6. Use according to claim 5, wherein the autoimmune disease is rheumatoid arthritis.

7. Bartonella quintana lipopolysaccharide or a functional equivalent fragment thereof for use as a medicament.

8. Medicament comprising Bartonella quintana lipopolysaccharide or a functional equivalent fragment thereof and one or more pharmaceutically acceptable excipients and/or carriers.

9. Method for treating an autoimmune or inflammatory disease comprising administering an therapeutic amount of Bartonella quintana lipopolysaccharide or a functional equivalent fragment thereof to a mammal suffering from an autoimmune, an autoinflammatory, or an infectious disease.

10. Method according to claim 9, wherein the mammal is a human mammal.

11. Use of a Toll-like 4 receptor (TLR-4) antagonist for the preparation of a medicament for the treatment of rheumatoid arthritis.

12. Use according to claim 11, wherein the Toll-like 4 receptor (TLR-4) antagonist is Bartonella quintana lipopolysaccharide (LPS) or a functional equivalent thereof.